BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BeyondSpring Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BeyondSpring Pharmaceuticals's dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07361484-2260@assetmemo.bio
DTSTAMP:20261121T005752Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Plinabulin: Phase 3 readout est. (NCT07361484)
DESCRIPTION:Plinabulin\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Doce
 taxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non
 -Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN
 -4)\nEstimated primary completion: 1 June 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/plinabulin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07361484
URL:https://assetmemo.bio/drug/plinabulin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
